Huperzine a CAS 102518-79-6 Huperzine a 1% 5% 98% Hupa Haboyin Hupzine a Huperizine Kimpukan a Isoselagine (-) -Selagine Huperzine a (P) Huperzine a Powder

• Certification: ISO, FDA
• Assay Method: HPLC, UV
• Application Form: Tablet, Capsule
• Application: Food, Health Care Products, Medicine, Cosmetic
• State: Slightly Yellow to White Crystalline Powder
• Extract Source: Huperzinaserrata(Thumb.)Trev
• Payment: T/T in Advance
• Shelf Life: 24 Months
• Delivery Time: 3-5 Working Days
• Free Sample: Available
• Transport Package: 25kg/Cardboard Drum I. D. 42cm X H. 52cm
• Specification: 1% 5% 98%
• Trademark: Shanghai, China
• Origin: China
• HS Code: 13021990
• Production Capacity: 20 Ton/Month

Product Description

Product Name:Huperzine A


CAS No.: 102518-79-6



Specification: 1% 5% 98%



Appearance:Slightly yellow to white crystalline powder



Test Method:HPLC

Product Profile

Huperzine A is a natural plant alkaloid extracted from the traditional Chinese medicine Huperzia plant Melaleuca. It is a potent, reversible and highly selective second-generation acetylcholinesterase inhibitor with a slightly yellow to white crystalline powder, easily soluble in chloroform, soluble in methanol, ethanol, slightly soluble in water, has high fat solubility, small molecule, can penetrate the blood-brain barrier well, and after entering the center, is mostly distributed in the frontal lobe of the brain. , temporal lobe, hippocampus and other brain areas closely related to learning and memory, have a strong inhibitory effect on acetylcholinesterase (AchE) at low doses, significantly increasing the acetylcholine (Ach) content in the synaptic gap in the distribution area. High, thereby enhancing neuron excitability conduction, strengthening the excitability of learning and memory brain areas, and playing a role in improving cognitive function, enhancing memory retention and promoting memory reproduction. It is currently the most successful drug developed in China to treat Alzheimer's disease.

Function and effect

Huperzine A is a reversible and potent cholinesterase inhibitor, stronger than physostigmine, neostigmine and Tacrine. It is used for myasthenia gravis with an effective rate of 99%.

Clinical trials have shown that this product is suitable for benign memory disorders. It can improve patients' pointing memory, associative learning, image recall, meaningless figure recognition and portrait recall. It also enhances the learning and memory of normal people; this product is good for patients with dementia. It can also improve memory impairment caused by organic brain lesions.

Clinically, Huperzine A can be used to treat the following symptoms:
1. Used to treat and improve memory function loss in middle-aged and elderly people, and improve associative recall function; used to treat memory loss caused by excessive brain use, and improve learning and work efficiency;
2. Used for memory loss associated with neurasthenia;
3. Huperzine A is used for memory loss caused by cerebrovascular disorders;
4. It is used to improve the memory of Alzheimer's disease, and has obvious effects on improving and restoring patients' cognitive and memory functions and improving emotional and behavioral abnormalities;
5. Used to treat myasthenia gravis;
6. Huperzine A can improve association disorders, cognitive dysfunction, memory loss, etc. associated with schizophrenia;
7. It can improve memory function associated with various brain diseases and physical diseases.

Applications

Huperzine A not only inhibits cholinesterase activity, but also affects the free radical system, reducing somatostatin, intracellular [Ca2+], and glutamate content, and increasing calmodulin (CaM) and calmodulin messengers. Ribonucleic acid (CaMmRNA) expression levels and other pharmacological mechanisms can improve cognitive function and learning and memory abilities.

Huperzine A can effectively prevent brain neurasthenia in middle-aged and elderly people, restore brain nerve function, and activate brain neurotransmitters. It is currently a new drug for the treatment of benign memory disorders.